Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Asthma review missed key options

We would like to raise concerns regarding significant deficiencies in the article ‘Evidence-based asthma care', a reproduction of a review by Map of Medicine, which appeared in your sister title Practical Commissioning (www.pulsetoday.co.uk/

practical-commissioning). 

The article highlights NICE guidance1 and states ‘ensure the least costly single combination device is prescribed when introducing a long-acting ß-agonist for patients already taking an inhaled steroid', but it does not reflect the complete evidence and treatment options available.

It mentions fluticasone/

salmeterol (Seretide) and budesonide/formoterol (Symbicort), but fails to mention the third and least costly combination on the market, beclometasone dipropionate/formoterol (Fostair), produced by Chiesi. 

Fostair has been shown in robust clinical trials to be comparable in efficacy to both Seretide and Symbicort.2,3  Fostair 100/6 is dose equivalent to Seretide 125/25 and Symbicort 200/6, as Fostair is characterised by an extra-fine particle size – resulting in greater distribution to small airways.

As such, 100µg of beclometasone dipropionate extrafine in Fostair is equivalent to 250µg of beclometasone dipropionate non-extrafine, achieving comparable efficacy at a lower steroid dose.4

Fostair 100/6, costing £29.32, is substantially cheaper than the dose equivalent to Seretide 125/25 (£35.00) and Symbicort 200/6 (£38.005). Articles published independently of Chiesi have highlighted that substantial savings could be made by reviewing and changing appropriate patients from Seretide and Symbicort to Fostair, ranging from £25,000 at CCG level6 to £7m at SHA level per annum.7

It is a significant deficiency of the methodology used that not all the available marketed products are reviewed, particularly ones that deliver equivalent efficacy at a lower nominal dose of steroid and at substantial saving to the NHS.

References

1 NICE. Inhaled steroids for the treatment of chronic asthma in adults and children aged 12 years and over. Technology Appraisal Guidance 138. London 2008

2 Papi A, Paggiaro P, Nicolini G et al. ICAT SE study group. Beclometasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007;62;1182-8

3 Papi A, Paggiaro PL, Nicolini G et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007;29:682-9

4 Summary of Product Characteristics. Fostair December 2011

5 MIMS. October 2011

6 Shailen R and Vinesh S. Reducing costs and raising quality of asthma prescribing. Prescriber 2011;22:39-417

7 East of England NHS PrescQipp Bulletin. June 2011. www.clingov.eoe.nhs.uk/prescqipp/

From Dr Helen Phillips, Medical director, Chiesi

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say